Early Life Feeding Exposure and Infant Immune and Health Status.
Mechanistic Effects of Early Life Feeding Exposure on Infant Inflammatory and Health Status
University of Idaho
60 participants
Jan 12, 2024
OBSERVATIONAL
Conditions
Summary
Background: Although breastfeeding has known protective effects, such as preventing childhood obesity, the specific mechanisms remain unclear. Idaho has a high breastfeeding initiation rate (92%) but a significant prevalence of childhood obesity (30.5% overweight/obese). Limited research exists on the impact of maternal inflammation, maternal body mass index (BMI), C-reactive protein (CRP), and interleukin-6 (IL-6) concentrations in breastmilk on infant health outcomes, especially in healthy full-term infants. Objective: This study aims to expand understanding of the role of maternal inflammation on breastmilk composition and its effect on infant immune development. The investigators seek to investigate the relationship between maternal health status, breastmilk inflammatory concentrations, and balanced immune development in infants. Additionally, the investigators aim to explore the potential influence of early diet exposure, including maternal inflammatory status, on the risk of obesity and other inflammatory conditions. Methods: Healthy full-term infants (breastfed/formula-fed) and their mothers will be recruited. Maternal inflammation markers (BMI, CRP, IL-6) and immune markers in infants will be analyzed. Flow cytometry will assess immune populations. Correlations between maternal systemic inflammation, infant inflammation, and breastmilk inflammatory markers will be examined for breastfeeding mothers. Outcomes: The investigators hypothesize breastfed infants will display a more favorable anti-inflammatory profile. This study will identify factors influencing immune development and potential pathways linking early-life exposures to long-term health outcomes. Findings will inform strategies for promoting balanced immune development and elucidate the role of early diet exposure, including maternal inflammation, as a protective or risk factor for obesity and inflammatory conditions.
Eligibility
Inclusion Criteria8
- Mother at least 18 years of age
- Mother is in third trimester (week 27 of gestation) or biological infant is 5 weeks of age or younger
- Mother plans to continue to provide your infant breastmilk (by breastfeeding or by pumping) for at least 18 weeks (4.5 months) from your delivery date or mother plans to continue to provide formula exclusively to infant for at least 18 weeks of life.
- Mother lives within a 45-mile radius of Study Site, or is willing to deliver samples for visits 2, 4, and 6.
- Mother willing to meet at (designated sample collection site) for visits 3 and 5 for sample collection and visit activities.
- Mother willing to consent and comply with all aspects of the study protocol and methods, save the optional activities and optional sample collections.
- Mother and infant are considered healthy by Principle Investigator.
- For Formula Fed Group: Mother-Infant dyad is able to match to a Breastfed dyad using maternal BMI and infant sex.
Exclusion Criteria4
- Mother or Infant have participated or are currently participating in an interventional drug or device (non-observational) research study before.
- Mother reports that they, or the infant, have had an adverse effect during a venous blood collection.
- Infant was born less than 36 weeks of gestation.
- Infant or mother have health conditions that increase the risk of study procedures.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study is only observational in nature and will not include an intervention.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05986539